Viking Therapeutics Inc (VKTX)

[DMOST]

The explanation can be summed up best by the this conclusive note:

Conclusion

The Phase 2 data on VK5211 was better than even the most optimistic expectations, and shows that the drug has robust activity with no safety concerns thus far. We’ll be interested to see how the development path evolves once the company is able to fully evaluate the final data package. We believe partnering VK5211 with a larger pharmaceutical company is now much more likely, although with very strong data Viking should be in no rush and can wait for the most optimal terms. Based on the results, we have increased our valuation from $7 to $11 and we continue to believe that Viking’s shares are significantly undervalued.

With that, we can't know what is totally going on behind the scenes.

There are a great deal of positives affront the bio-pharmaceutical sector of late. And VKTX has at least two prime drugs waiting for later phase testing that can be game changers, to included VK5211 for Hip Fracture and VK2809 NASH orally ingested medication.

They are out there waiting, watching, assessing and making plans for negotiations..............WE CAN WAIT A BIT LONGER, ITS COMING.

GO VKTX

"PEACE"